```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory compound extensively employed in thrombosis research . This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on thrombocytes , blocking thrombus development. Consequently , it's often investigated as a technique to examine the pathways underlying clotting and to determine the website performance of antiplatelet therapies. Distribution is typically restricted to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 and 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a antiplatelet agent, frequently employs the monoclonal antibody C7E3 and the molecule identified as 143653-53-6. These reagents are crucial for investigating abciximab's mode of function, determining its efficacy in various clinical settings, and elucidating potential indicators of patient outcome. Further study leveraging these specific reagents is predicted to yield valuable insights for improving therapeutic strategies concerning cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Potential Avenues with the Drug Abciximab 143653-53-6 and C7E3
Recent studies suggest that the drug (identified as 143653-53-6) presents significant scientific value, particularly when associated with C7E3. Initial observations have that this combination may enhance patient responses in multiple cardiovascular settings. Further exploration is centered on defining the exact mechanism of interaction between this inhibitor and C7E3, including assessment of blood clot cohesion and vascular safeguarding.
- Future research work seek to maximize delivery approaches.
- Animal systems are are being utilized to additional validate such theories.
- Human trials will be required to thoroughly evaluate clinical benefit.
```
Abciximab (C7E3) for Research: Purity and Specifications (143653-53-6)
Researchers requiring this antibody for in vitro investigations should meticulously assess purity and defined parameters . Material 143653-53-6 is typically provided as a lyophilized powder and thorough analytical data including identity by HPLC , binding affinity assays, and endotoxin testing are available. Ensure the supplier's certificate of analysis outlines defined limits for contaminants and meets all quality control guidelines.
Research-Grade Abciximab Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires careful consideration of its source . This antibody is widely utilized in laboratory studies , particularly those related to platelet clumping and thrombosis . Available sources offer this material in varying amounts , typically ranging from mg to significant commercial amounts . Kindly advise reviewing the report of quality to verify quality and appropriateness for your specific use . Furthermore , confirm the stability date before procuring to maintain optimal performance .
- Common Purity: >95%
- Preservation Conditions: -20°C in controlled conditions
- Application : Platelet Clumping Suppression Studies